MyMD Pharmaceuticals, Inc. MYMD stock price (” MyMD” or “the Business”), a clinical stage pharmaceutical company committed to prolonging healthy life expectancy, today revealed that the first patient has actually been enlisted in the Business’s Phase 2 professional trial of lead candidate MYMD-1, a dental immune regulatory authority medicine, as a therapy for delaying aging and increasing healthy and balanced lifespan.
The key endpoint for the Phase 2 double-blind, placebo-controlled scientific trial is to attain a reduction in the circulating degrees of (TNF-α), lump necrosis aspect receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the healthy proteins in the body that trigger inflammation and aid turn on the procedure of aging. The second procedures of the test will certainly be the safety, tolerability, and also pharmacokinetics in this populace of people.
” In a Phase 1 professional test of MYMD-1, we demonstrated the medication’s statistically substantial efficacy in reducing levels of TNF-α, a principal in creating pathological aging, in the blood. The FDA has accepted TNF-α reduction as the main endpoint for our Phase 2 research, which our company believe placements us well for a successful Stage 2 outcome,” stated Chris Chapman, M.D., Head Of State, Director and also Principal Medical Officer of MyMD. “The initiation of individual enrollment in this research developments our goal to slow down the aging procedure, stop loss of muscle tissue in aging, limit frailty, and also extend healthy life-span.”
MyMD has actually stated that there are no FDA-approved medications for treating aging disorders and prolonging healthy life expectancy human beings, a market expected to be a minimum of $600 billion by 20251 according to a major investment bank. TNF-α blockers are one of the most recommended drugs by revenue, a worldwide market of around $40 billion per year,2 and, according to Nature Aging journal,3 a stagnation in maturing that would boost life expectancy by one year deserves $38 trillion as well as by 10 years is worth $367 trillion.
Along with aging, MYMD-1’s unique activity in regulating the immune system as well as dealing with chronic swelling is being created for the treatment of autoimmune condition, including rheumatoid joint inflammation (RA), numerous sclerosis (MS), diabetes mellitus, as well as inflammatory digestive tract condition.
” We plan to begin composing protocols for a Stage 2 pilot study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The rising occurrence of rheumatoid arthritis as well as other autoimmune and inflammatory illness are driving need for TNF inhibitors like MYMD-1, and we believe our by mouth carried out drug with extremely reduced toxicity would certainly be disruptive to the $60 billion market for RA if approved by the FDA for this indicator.”
Rheumatoid joint inflammation affects roughly 40 million individuals around the world.4.
Originally developed for autoimmune conditions, MYMD-1’s primary purpose is to reduce the aging process, avoid sarcopenia as well as frailty, as well as expand healthy life expectancy. Since it can go across the blood-brain obstacle and gain access to the central nerve system (CNS), MYMD-1 is likewise positioned to be a feasible treatment for brain-related disorders. Its mechanism of activity and also efficiency in conditions including numerous sclerosis (MS) as well as thyroiditis have actually been researched with partnerships with several scholastic organizations. MYMD-1 is additionally revealing assurance in pre-clinical researches as a possible treatment for article- COVID-19 problems and also as an anti-fibrotic as well as anti-proliferation restorative.
MYMD-1 has shown performance in pre-clinical research studies in controling the body immune system by doing as a discerning inhibitor of lump necrosis factor-alpha (TNF-α), a vehicle driver of persistent swelling. Unlike other therapies, MYMD-1 has actually been displayed in these pre-clinical studies to uniquely block TNF-α when it ends up being overactivated in autoimmune conditions and cytokine storms, yet not obstruct it from doing its normal job of being a first responder to any kind of routine kind of modest infection. MYMD-1’s ease of dental application is one more differentiator compared to currently readily available TNF-α blockers, all of which call for delivery by shot or infusion. No approved TNF inhibitor has ever been dosed orally. Additionally, the medication is not immunosuppressive as well as has actually not been shown to create the severe negative effects typical with typical therapies that deal with swelling.
Concerning MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical business dedicated to extending healthy and balanced life expectancy, is focused on developing 2 novel therapeutic systems that treat the reasons for disease as opposed to just addressing the signs. MYMD-1 is a drug system based upon a medical stage little particle that regulates the immune system to regulate TNF-α, which drives persistent inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to postpone aging, boost longevity, and deal with autoimmune illness as well as COVID-19- linked clinical depression. The Company’s 2nd drug platform, Supera-CBD, is being created to deal with chronic pain, addiction as well as epilepsy. Supera-CBD is an unique synthetic by-product of cannabidiol (CBD) as well as is being established to address and surpass the quickly growing CBD market, that includes both FDA authorized medications and CBD products not currently regulated as medications. For additional information, check out www.mymd.com.